DRUG UTILIZATION REVIEW BOARD
JULY 15, 2009
205 JEFFERSON STREET JEFFERSON CITY MO 65101

DUR BOARD MEMBERS PRESENT
John Newcomer, MD, Chairman
Charlene Heyde, RPh
Susan Abdel-Rahman, PharmD
Jennifer Passanise, FNP
Sandra Bollinger, PharmD
Peggy Wanner-Barjenbruch, MD

DUR BOARD MEMBERS ABSENT
Sharad Parikh, MD
David Campbell, MD
Joy Gronstedt, DO
Joseph Yasso, DO
Stacy Mangum, PharmD
Randy Beckner, PharmD

OTHERS IN ATTENDANCE
P. Winigbermuehle, Astra Zeneca
Don Larsen, Forest
Shel Buck, Pamlab
Jessica North
Lisa Whitson
Joan Houston
Chris Wycinowski, Pfizer
Richard Mesquias, Eli Lilly
Joe Summers, Takeda
Lindsay Davis
Barbara Belcher, Merck
Jeff Knappen, Allergan
Debbie King, Amgen
John Harris, Abbott
Jeff Himmelburg, GSK
Phil King, Pfizer
Conan Esindvey, Pfizer
Rob Kilo, Pfizer
Diane Racicot, Strativa

MHD STAFF PRESENT
George L. Oestreich, PharmD, Deputy Division Director
Rhonda Driver, RPh, Director Pharmacy Program
Jay Bryant Wimp, RPh, Clinical Pharmacist
Jayne Zemmer, Program Manager
Andrew Haslag, Fiscal Manager
Tisha McGowan, Unit Supervisor
Beth McQuaide, Special Assistant
Mary Heet, RN
Jenna Twehus, RN
Jackie Hickman, Unit Supervisor
Renee Riley, Medicaid Specialist
Chick Pullam, Correspondence and Information Specialist

CONTRACTED STAFF PRESENT
Jennifer Kemp-Cornelius, PharmD, ACS
Mark Roaseau, MD, PharmD, ACS
Rick Pope, PharmD, First Health
Tom Beetem, RPh, IFOX
Annette Walther, RN, IFOX
Geri Roling, RN, IFOX
Bethany Noble, ACS
Cate Rudder, Student Intern

*****Many names on the sign in sheet were illegible. Sign in sheet on file for review.

Welcome, Introductions and Opening Remarks	Chairman, John Newcomer, M.D. called the meeting to order at 10:00 a.m. A quorum was not established and the Board met as a Committee of the Whole. A follow up conference call will be scheduled to ratify any recommendations made. A folder of correspondence, pertaining to the agenda topics, received and responded to during the quarter was shared with the Board. A copy of this correspondence is available to Board members upon request. Cate Rudder, a pharmacy student completing her internship with the Clinical Services Unit, was introduced.
Minutes Approval	Minutes of the May 12, 2009 conference call were reviewed and approved as submitted.
Pharmacy Program/Budget Update	George L. Oestreich, PharmD, MPA, Deputy Division Director presented a PowerPoint presentation entitled *Aligning Forces for Quality and Efficacy.* Slides presented were to share information regarding the end of Fiscal Year 2009, the beginning of Fiscal Year 2010 as well as to discuss the American Reinvestment and Recovery Act (ARRA) Health Information Technology (HIT) projects the Division is focused on. He noted the Division plans to concentrate on high spend therapeutic classes as well as issues associated with the utilization of psychotropic medications for children with a focus on best practices and outcomes for our participants during the current fiscal year. Slides included average weekly pharmacy expenditures, average prescription charge, cost per eligible per work day, and Medicaid eligible growth rate trend lines. The Division is monitoring economic concerns and potential federal guidelines that may significantly affect eligibility. It was noted that per member per month data will be used again by the pharmacy program. Dr. Oestreich discussed the current electronic tools available for clinical use and those tools available for participant use. He reviewed current features of each tool as well as near and later term additions planned. An in-depth demonstration of the Medication Possession Ratio feature within CyberAccess® as well as changes to the tool that will allow it to interact with existing systems might be scheduled for a future meeting. He continued the presentation by discussing how the state partners, including the Departments of Social Services, Mental Health and Health and Senior Services, are working together to plan a statewide HIT Strategic Plan and the role of the state and private sector partners as we work toward a statewide health information exchange. Dr. Oestreich concluded with a discussion of program performance, including the impact of eligibility, and off trend savings for all interventions though Fiscal Year 2009. Questions from the Board and audience were responded to throughout the presentation. In response to a question from the Board Dr. Oestreich clarified the pulling back of the Administrative Services Organization (ASO) model effective July 1, 2009 and plans for the Chronic Care Improvement Program (CCIP) throughout the state. Copies of slides used will be available on the MO HealthNet Division's Web-page. (http://dss.mo.gov/mhd) clinical services advisory group page. (http://dss.mo.gov/mhd/cs/advisory/index.htm.
Review of Prior Authorization Meeting:	Copies of the agenda and draft minutes, including public hearing, from the June 18th 2009 *Drug Prior Authorization Meeting* were included in the members' meeting packet.
Implementation Schedule	An updated copy of the *Proposed Implementation Schedule for Edits,* including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The schedule had

	been updated with all edits approved at the last quarter's meetings. This schedule may be found on the MHD web page at http://dss.missouri.gov/mhd/cs/pharmacy/pdf/impsched.pdf
New Drug Review	• **Discussion -** Drug monographs were available for review at http://www.heritage-info.com/mocaidrx for all new products reviewed this quarter (Identified by First Data Bank in January, February, and March). A listing of products recommended for open access, clinical edit, as a PDL product or for continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout (see meeting packet) to all attending. Jay Bryant Wimp, RPh, Clinical Pharmacist reviewed MHD recommendations as well as a request from the Drug Prior Authorization (PA) Committee for a Drug Information Center review for the product Aplenzin®. Pfizer Pharmaceuticals requested time to provide efficacy and safety information on the product Toviaz®. • **Decision –** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. New Drug recommendations were included in this block vote and approved as submitted. (See Roll Call Vote)
Clinical Edits **Selzetry®**	• **Discussion –** A copy of the proposed criteria surrounding this product was included in the meeting packet and provided to all attendees. Mr. Bryant Wimp reviewed the document explaining the Division's approval criteria which includes a positive Trofile® test. • **Decision –** Following this discussion the Board approved the recommendation as presented.
Trofile	• **Discussion —** A copy of the proposed criteria surrounding this product was included in the meeting packet and provided to all attendees. Mr. Bryant Wimp reviewed the criteria and summarized the Drug PA Committee recommendation that the approval criteria be amended to include the test is being ordered by an appropriately trained physician. Discussion ensued regarding how this would be determined and would an inappropriate barrier be placed on access. • **Decision –** A motion to remove the criteria proposed by the Drug PA Committee to edit the physician type ordering the test, but to monitor for inappropriate use for approximately six months post implementation was made. With this change the edit was approved as submitted.
Suboxone®	• **Discussion –** A copy of the proposed criteria updates surrounding this product was included in the meeting packet and provided to all attendees. Mr. Bryant Wimp noted additional information added included denial criteria surrounding use during pregnancy and additions to approval criteria to allow the patient to be enrolled in other substance abuse programs or mental health treatment services, recognized by the Department of Mental Health (DMH) Division of Alcohol and Drug Abuse, in addition to CSTAR. Discussion ensued surrounding safety and the use of a benzodiazepine while on Suboxone® therapy. Rhonda Driver, RPh, Director of Pharmacy reminded that this edit is not transparent, as the SAMSA Waiver must be verified prior to approval. • **Decision –**Members asked that the denial criteria surrounding a benzodiazepine prescription while on Suboxone ® be clarified and requested the statement be changed to "No concurrent use of a benzodiazepine." Members also requested an educational mailing be sent to providers known to prescribe this product prior to implementation of the edit. With these changes the edit recommendation was approved.

Xolair®	• **Discussion –** A copy of the proposed updates to the criteria surrounding this product was included in the meeting packet and provided to all attendees. Mr. Bryant Wimp reviewed the additions to the approval criteria which included adding RAST or in vitro reactivity testing in addition to skin testing as well as to clarify trial and failure on Inhaled corticosteroids to be defined as inadequate or poor asthma symptom control. Discussion surrounding initial prescribing for the product vs. maintenance prescriptions ensued. Members felt the requirement for the prescriber to be a specialist in the fields of allergist, immunologist or pulmonologist should only pertain to the initial prescription. • **Decision –** The motion to remove the specialist criteria from refills/maintenance prescriptions of the product was made. Members approved the updates to the edit with this change in approval criteria.
Preferred Drug List (PDL)	Products and classes under review this quarter have existing contracts through September 30, 20009. Recommended changes to the edits were bolded for easy identification.
Beta Adrenergic Blockers and Diuretic Combinations	• **Discussion –** Mr. Bryant Wimp reviewed the criteria document included in the meeting packet. Preferred and non preferred products were reviewed as well as approval and denial criteria. A new product Nadolol/Bendroflumethiazide was added to non-preferred status. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Calcium Channel Blockers/Dihydropyridines	• **Discussion –** Mr. Bryant Wimp reviewed the criteria document including preferred and non-preferred products and approval/denial criteria. The addition of new product Nisoldpine to non-preferred status was noted. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Calcium Channel Blockers/Nondihydropyridines	• **Discussion –** Mr. Bryant Wimp reviewed the criteria document pointing out no changes were recommended to the current edit. • **Decision -** This PDL recommendation was accepted as presented and added to the block vote. (See Roll Call Votes)
Angiotensin II Receptor Calcium Channel Blocker Cominations	• **Discussion –**Mr. Bryant Wimp reviewed the criteria document noting no change to the current edit. • **Decision -** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Cox II Inhibitors	• **Discussion –**Mr. Bryant Wimp reviewed the criteria document. No change was recommended. • **Decision -** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Hepatitis C Agents	• **Discussion –** Mr. Bryant Wimp reviewed the criteria document noting all products within the class remain as preferred. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Amylin Analogs	• **Discussion –** Mr. Bryant reviewed the criteria document noting no change to the current edit. All products within the class remain preferred and approval criteria will remain in place. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call

	Votes)
GLP-1 Receptor Agonists	• **Discussion –** Mr. Bryant Wimp reviewed the criteria document including approval/denial criteria. No change was recommended for this class. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
DDP-IV Inhibitors	• **Discussion –** Mr. Bryant Wimp reviewed the criteria document including approval/denial criteria. No change was recommended. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Onychomycosis Antifungals	• **Discussion –** Mr. Bryant Wimp reviewed the criteria document including preferred and non-preferred products. No change to the current edit was recommended. Ms. Driver clarified indications for Sporanox ® Solution in response to a question raised by the Board. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Proton Pump Inhibitors	• **Discussion –** Mr. Bryant Wimp reviewed the criteria document including preferred and non-preferred products. Prilosec® Rx Caps/Susp, Zegerid® Caps/Packet and Kapidex Capsules were moved to the non-preferred agent's side of the edit. Discussion ensued regarding recent concerns surrounding adverse interaction with Plavix®. Dr. Oestreich will share a recent article on the subject with the members. • **Decision –** This PDL recommendation was accepted and added to the block vote. Members also recommended a news letter be devoted to the Plavix® concerns. (See Roll Call Votes)
Ribvirins	• **Discussion –** Mr. Bryant Wimp reviewed the criteria document noting no change to the current edit. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Topical Immunomodulators	• **Discussion –** Mr. Bryant Wimp summarized the criteria document noting no change to the current edit was recommended. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Topical Androgenic Agents	• **Discussion –** Mr. Bryant Wimp reviewed the criteria document noting no change to the current edit. A new product Trilipix® was introduced to the class and recommended for preferred status. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
ACS Healthcare Update	Jennifer Kemp-Cornelius, PharmD. ACS Healthcare Systems summarized the current clinical edit for skeletal muscle relaxants. Slides shared provided claim counts, paid amounts per participant and utilization data. Helpdesk approval/denial statistics were also shared. Dr. Kemp-Cornelius explained at each Drug Utilization Review Board meeting she would like to pick an edit that is not routinely reviewed each year as she reviewed each of the documents. This information can be shared with the PA Committee if there is an interest. The next topic will be the ADHD clinical edit.

Preferred Drug List Discussion/Therapeutic Classes	A handout of therapeutic categories to be considered for inclusion on the PDL for the next quarter and meeting was provided in the meeting packet and to all attendees. These categories will be an annual review of products with contracts expiring December 31, 2009. The Division will also post these classes to the Web page http//:www.dss.mo.gov/mhd..
Program Statistics:	
Top 25 Drugs by Cost	Top 25 drug lists for the, 4th quarter of 2008 and the first five months of 2009 were provided for the Boards' information. These reports were provided by number of claims and amount paid format. Copies were available to all attendees.
Clinical Edit Summary Report	An overview report of the clinical edit and prior authorization request transaction counts for the months of May and June 2009 was provided for all attending. The report detailed total transaction counts as well has information on the outcome (approval or denial) of the request.
Call Center Statistics	A handout illustrating pharmacy help desk call center activity was provided for all attending. Statistics for May and June 2009 were included. Also included for the Boards' information was a CyberAccess™ Report. This report detailed statistics for CyberAccess™ usage from April 2006 through June 2009 and showed how usage has grown overtime and as edits are implemented.
Program Utilization Information/Other Business	Ms. Driver informed the Board that the Governor's Office was in the process of updating their Web-site and had requested a mission statement from the DUR Board for inclusion. MHD reviewed the current statement and felt it did not reflect the expanded mission of the Board. A draft of an updated statement was included for the review and approval of the group. Minor changes were recommended and the new mission statement was approved. (see roll call votes) Members were provided with an updated copy of the Statins PDL edit. Ms. Driver pointed out the addition to approval criteria addressing the high potency Statins and secondary prevention criteria as recommended by the Board in their previous meeting. Ms. Driver responded to questions regarding the exchange of claims data and grandfathering for the Managed Medicaid carve-out of pharmacy services effective October 1, 2009.
Adjourn	The DUR Board went into Executive Session for the sole purpose of discussing individual participant specific medical information. At the conclusion of these discussions the group adjourned entertaining no further business, actions or motions. (See attached roll call vote) The next meeting is scheduled for October 21, 2009.

Roll Call Votes – July 15, 2009

Member	***Minutes***	**Drug PA Review**	**Trofile Selzentry**	**Suboxone**	***Xolair***	***Mission Statement***	***Close Session***	***Adjourn***
Susan Abdel-Rahman	***Motion***	**Second**	**Second**	Yeah	Yeah	Yeah	Yeah	Yeah
Randy Beckner	*Absent*	*Absent*	*Absent*	*Absent*	*Absent*	*Absent*	*Absent*	*Absent*
Sandra Bollinger	***Second***	Yeah	Yeah	**Second**	Yeah	**Second**	**Second**	Yeah
Jennifer Passanise	Yeah	Yeah	Yeah	Yeah	**Motion**	Yeah	Yeah	Yeah
David Campbell	*Absent*	Absent	Absent	Absent	*Absent*	*Absent*	*Absent*	Absent
Joy S. Gronstedt	*Absent*	*Absent*	*Absent*	*Absent*	*Absent*	*Absent*	*Absent*	*Absent*
Stacy Mangum	*Absent*	*Absent*	*Absent*	*Absent*	*Absent*	*Absent*	*Absent*	*Absent*
John Newcomer	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah
Sharad Parikh	*Absent*	*Absent*	*Absent*	*Absent*	*Absent*	*Absent*	*Absent*	*Absent*
Charlene Heyde	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	**Motion**	**Second**
Peggy Wanner-Barjenbruch	Absent	**Motion**	**Motion**	**Motion**	**Second**	**Motion**	Yeah	**Motion**
Joseph M. Yasso	*Absent*	*Absent*	*Absent*	*Absent*	*Absent*	*Absent*	*Absent*	*Absent*

EXECUTIVE SESSION
July 15, 2009

DUR BOARD MEMBERS PRESENT
John Newcomer, MD, Chairman
Charlene Heyde, RPh
Susan Abdel-Rahman, PharmD
Jennifer Passanise, FNP
Sandra Bollinger, PharmD
Peggy Wanner-Barjenbruch, MD

DUR BOARD MEMBERS ABSENT
Sharad Parikh, MD
David Campbell, MD
Joy Gronstedt, DO
Joseph Yasso, DO
Stacy Mangum, PharmD
Randy Beckner, PharmD

MHD STAFF PRESENT
George L. Oestreich, PharmD, Deputy Division Director
Rhonda Driver, RPh, Director Pharmacy Program
Jay Bryant Wimp, RPh, Clinical Pharmacist
Jayne Zemmer, Program Manager
Andrew Haslag, Fiscal Manager
Tisha McGowan, Unit Supervisor
Beth McQuaide, Special Assistant
Mary Heet, RN
Jenna Twehus, RN
Jackie Hickman, Unit Supervisor
Renee Riley, Medicaid Specialist
Chick Pullam, Correspondence and Information Specialist

CONTRACTED STAFF PRESENT
Jennifer Kemp-Cornelius, PharmD, ACS
Mark Roaseau, MD, PharmD, ACS
Rick Pope, PharmD, First Health
Bethany Noble, ACS
Cate Rudder, Student Intern

Minutes Review	Minutes of the April Executive Session were approved as submitted
Case Reviews	Two cases were presented by Jenna Twehaus, RN for review and recommendation by the Board. Members made recommendations for interventions in both cases.
Adjourn	Executive session adjourned. (See role call vote)